Ultragenyx Pharmaceutical Inc.RARENASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank36
3Y CAGR-18.8%
5Y CAGR-30.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-18.8%/yr
vs -31.8%/yr prior
5Y CAGR
-30.6%/yr
Recent acceleration
Acceleration
+12.9pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
5 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 4.62 | -29.6% |
| 2024 | 6.56 | -14.9% |
| 2023 | 7.71 | -10.8% |
| 2022 | 8.64 | -44.2% |
| 2021 | 15.47 | -46.0% |
| 2020 | 28.62 | +47.0% |
| 2019 | 19.47 | -51.1% |
| 2018 | 39.83 | -94.4% |
| 2017 | 715.35 | -96.4% |
| 2016 | 19716.06 | - |